Established clinical guidelines advocate that decisions regarding treatment options should be based on a comprehensive evaluation of tumor features, baseline prostate-specific antigen (PSA) levels, patient age, comorbidity, life expectancy, and quality of life [6–8]. This evidence concerns the gene KLK3 and neoplasm.